The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results

被引：0
|
作者：
Feagan, Brian G. [1 ]
Sands, Bruce E. [2 ]
Siegel, Corey A. [3 ]
Dubinsky, Marla C. [4 ]
Longman, Randy [5 ]
Sabino, Joao [6 ]
Laurent, Olivier [7 ]
Luo, Allison [7 ]
Lu, J. D. [7 ]
Nguyen, Deanna D. [7 ]
Towfic, Fadi [7 ]
DuVall, Aaron [8 ]
Woynarowski, Marek [9 ]
Al Kharrat, Houssam [10 ]
McGovern, Dermot [11 ]
机构：
[1] Western Univ, London, ON, Canada
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Dartmouth Hitchcock Med Ctr, Dartmouth Hitchcock Inflammatory Bowel Dis Ctr, Lebanon, NH 03766 USA
[4] Mt Sinai Kravis Childrens Hosp, New York, NY USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] Univ Hosp Leuven, Leuven, Brussels Hoofds, Belgium
[7] Prometheus Biosci Inc, San Diego, CA USA
[8] Tyler Res Inst LLC, Tyler, TX USA
[9] UJK Kielce, Kielce, Swietokrzyskie, Poland
[10] West Texas Digest Dis Ctr, Lubbock, TX USA
[11] Cedars Sinai Med Syst, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1143
引用
收藏
页码：S875 / S876
页数：2
相关论文
共 27 条
  • [1] The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
    Feagan, B. G.
    Sands, B.
    Siegel, C. A.
    Dubinsky, M.
    Longman, R.
    Sabinho, J.
    Laurent, O.
    Luo, A.
    Lu, J. D.
    Nguyen, D.
    Towfic, F.
    DuVall, A.
    Woyranowski, M.
    Al Kharrat, H.
    McGovern, D. P. B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I162 - I164
  • [2] Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
    Danese, Silvio
    Klopocka, Maria
    Scherl, Ellen J.
    Romatowski, Jacek
    Allegretti, Jessica R.
    Peeva, Elena
    Vincent, Michael S.
    Schoenbeck, Uwe
    Ye, Zhan
    Hassan-Zahraee, Mina
    Rath, Natalie
    Li, Gang
    Neelakantan, Srividya
    Banfield, Christopher
    Lepsy, Christopher
    Chandra, Deepa E.
    Hung, Kenneth E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (11) : 2324 - +
  • [3] Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn's Disease (RELIEVE UCCD)
    Reinisch, W.
    Stoyanov, S.
    Raphael, G.
    Barkay, H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1802 - I1802
  • [4] Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Crohn's Disease (CD): Results from the Open-Label Extension Period of the Phase 2 APOLLO-CD Study
    Siegel, Corey A.
    Leong, Rupert W.
    Anderson, Jaclyn K.
    Yen, Mark
    Dong, Bin
    Sands, Bruce E.
    Danese, Silvio
    Feagan, Brian G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1000 - S1000
  • [5] Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study
    Bril, Vera
    Benatar, Michael
    Brock, Melissa
    Greve, Bernhard
    Kiessling, Peter
    Woltering, Franz
    Van den Bergh, Peter
    NEUROLOGY, 2019, 92 (15)
  • [6] Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
    Danese, S.
    Klopocka, M.
    Scherl, E. J.
    Romatowski, J.
    Allegretti, J. R.
    Peeva, E.
    Vincent, M. S.
    Schoenbeck, U.
    Xi, L.
    Ye, Z.
    Hassan-Zahraee, M.
    Rath, N.
    Li, G.
    Neelakantan, S.
    Banfield, C.
    Lepsy, C.
    Chandra, D.
    Hung, K. E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S109 - S109
  • [7] SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY
    Danese, Silvio
    Klopocka, Maria
    Scherl, Ellen J.
    Romatowski, Jacek A.
    Allegretti, Jessica R.
    Peeva, Elena
    Vincent, Michael S.
    Schoenbeck, Uwe
    Xi, Li
    Ye, Zhan
    Hassan-Zahraee, Mina
    Rath, Natalie
    Li, Gang
    Neelakantan, Srividya
    Banfield, Christopher
    Lepsy, Christopher
    Chandra, Deepa
    Hung, Kenneth E.
    GASTROENTEROLOGY, 2020, 158 (06) : S206 - S207
  • [8] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 13
  • [9] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
    Swanson, Chad J.
    Zhang, Yong
    Dhadda, Shobha
    Wang, Jinping
    Kaplow, June
    Lai, Robert Y. K.
    Lannfelt, Lars
    Bradley, Heather
    Rabe, Martin
    Koyama, Akihiko
    Reyderman, Larisa
    Berry, Donald A.
    Berry, Scott
    Gordon, Robert
    Kramer, Lynn D.
    Cummings, Jeffrey L.
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [10] Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 14
123